Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Repligen has recruited first patient in a pilot study to assess the ability of RG1068 for improving detection and characterization of pancreatic cancer.
Subscribe to our email newsletter
RG1068, a synthetic version of the hormone secretin, is known to both stimulate the secretion of pancreatic fluid into the pancreatic ducts and to increase blood flow to the tissues of the pancreas.
The study is expected to recruit up to 40 patients with a known or suspected pancreatic mass and will also investigate which imaging technique is optimal for pancreatic tumor detection, staging and evaluation for surgery.
The addition of RG1068 to standard contrast-enhanced imaging techniques which are currently ineffective in resolving early disease may enable the tumor to become more visible.
Principal investigator of the study Pablo Ros said RG1068 has the potential to improve the ability to detect and correctly stage pancreatic tumors by CT and MRI scans and may lead to improved patient outcomes.
In previous Phase 3 studies, RG1068 has shown improvement in detection of pancreatic duct abnormalities in combination with MRI in patients with pancreatitis.